Risk of Liver Damage Caused by Modern Systemic Antimycotics
Authors:
M. Skořepová
Authors‘ workplace:
Kožní klinika 1. LF UK a VFN, Praha přednosta doc. MUDr. J. Štork, CSc.
Published in:
Čes-slov Derm, , 2004, No. 2, p. 59-61
Category:
Overview
Long-term systemic antimycotic therapy, which is necessary in dermatology indications as e.g.in onychomycosis, is associated with concern of certain risk of hepatotoxicity. The frequency of liverdamage after application of ketoconazole is 1:15 000, after terbinafine 1:45 000-50 000, after itraconazolepulse-therapy 3.2:100 000 and after intermittent fluconazole therapy 1.4:100 000. The safety ofmodern antimycotics is comparable e.g. with paracetamol (toxic reactions rate 5.5:100 000) oribuprofen (toxic liver damage appeared in 2 of 54 830 treated).
Key words:
systemic antimycotics - hepatotoxicity
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2004 Issue 2
Most read in this issue
- Risk of Liver Damage Caused by Modern Systemic Antimycotics
- Fibrous and Fibrohistiocytic Skin Tumors: Clinical Cases of Atypical (Pseudosarcomatous)Benign Fibrous Histiocytoma and Atypical Fibroxanthoma
- Primary Cutaneous Follicular Center Cell Lymphoma
- Contact Hypersensitivity to Allergens Contained in Cosmetic Products - ReactionsAssessed by European Standard Allergen Set